Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iadademstat + ICI Maintenance in Extensive-Stage SCLC
NCT06287775Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2025
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iadademstat in small cell lung cancer (SCLC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 2 years. Started Apr 2025; status: recruiting.
02
Drugs
iadademstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06287775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287775.